It is likely that MMP9 from neutrophils is contributing to the phenotype in the experimental metastasis assay. the percent of tumor cells undergoing apoptosis compared to control mice. We conclude that MMP9 from your bone marrow contributes to the early survival and establishment of tumors in the lung and has no effect on subsequent growth. These results provide insights into the failure of MMP inhibitors in medical trials in individuals with late stage lung malignancy. Apoptosis Detection Kit (Chemicon International, Temecula, CA) relating to manufacturers directions. Nuclei were counterstained with Hoechst 33258. Labeling of tumor cells CellTracker? probe (CellTracker Reddish CMPTX) (Molecular Probes, Eugene, OR) (10M) was added to the cell tradition medium at a dilution of 1 1:1000. Cells were labeled for 30 min. Labeled cells were visualized using Axioplan 2 imaging microscope (Zeiss) and Openlab 4.0.2 software. Statistical Analysis All data generated using the experimental metastasis assays were analyzed using a non-parametrical (Mann-Whitney) method. Data generated using the orthotopic model were analyzed using Fishers precise test. (Statview software, SAS Institute). RESULTS Host MMPs contribute to the establishment of tumors in the lung In order to determine if host-derived MMPs contribute to lung tumor colonization, experimental metastasis assays were performed by injecting 3 x 105 Lewis lung carcinoma cells (LLC) into the tail vein of syngeneic C57Bl/6 wildtype mice or MMP2, MMP7 or MMP9 null mice. Two weeks after tail vein injection, the surface lung tumors were counted and measured. In contrast to earlier reports (15), we saw no difference in tumor quantity comparing control and MMP2 null mice (Fig. 1A). Remarkably, MMP7 null mice showed a 42% increase in tumor quantity compared to control mice (p=0.01), suggesting a protective effect of MMP7 on lung colonization (Fig. 1C). Most interestingly, MMP9 null mice showed an 81% reduction in tumor quantity compared to wildtype mice (p=0.0002) (Fig. 1E). The results from the MMP9 null mice are in agreement with those previously reported (16) although the effect of MMP9 ablation on tumor quantity was greater in our study. There was no significant difference in tumor size in any of the MMP null mice compared to wildtype mice (Fig. 1B,D,F), suggesting that these MMPs are not having an effect on the growth of tumors that successfully set up in the lung. These experiments display that different host-derived MMPs can have different effects on metastasis to the lung. Because MMP9 null mice showed probably the most dramatic phenotype, we chose to pursue this observation to understand the mechanism by which MMP9 contributes to lung tumor development. Open in a separate window Number 1 Host MMP contributions to lung tumor formation. (A) Quantity of surface lung tumors in control (n=12) and MMP2 null (n=12) mice 2 weeks after injection of 3 x 105 LLC cells i.v. (p=NS). (B) Tumor size in control and MMP2 null mice (p=NS). (C) Quantity of surface lung tumors in control (n=14) and MMP7 null (n=14) mice 2 weeks after injection of 3 x 105 LLC cells i.v. (*p=0.01). (D) Tumor size in control and MMP7 null mice (p=NS). (E) Quantity of surface lung tumors in control (n=13) and MMP9 null (n=11) mice 2 weeks after injection of 3 x 105 LLC cells i.v. (*p=0.0002). (F) Tumor size in control and MMP9 null mice (p=NS). MMP9 contributes to the establishment of a main tumor in the lung To test if sponsor MMP9 also has an effect within the establishment of main tumors in the lung, an orthotopic model of lung malignancy was founded by injecting human being lung carcinoma A549 cells directly into the lung via the trachea. This procedure produces distinct main tumors in the lung in 5 weeks (Fig. 2A). 1×106 A549 cells were injected into either immunocompromised Rag2 null mice or immunocompromised Rag2/MMP9 null mice and tumor growth was examined after 5 weeks. Tumors develop in 82% of wildtype mice compared to 44% of MMP9 null mice, suggesting a contribution of sponsor MMP9 to initial tumor take (Table. 2B). However, when comparing tumors that develop in either the wildtype or MMP9 null animals, approximately 50% in each case can be classified as microscopic ( 0.1mm diameter) and approximately 50% are macroscopic with sizes ranging from 0.5 C 87 mm3 (Table 2C). This suggests that the presence Rabbit Polyclonal to SEMA4A or absence of MMP9 is definitely.However, of the tumors that did develop in the lung, tumors in MMP9 null mice were able to convert to macroscopic size in figures equivalent to control mice. subsequent growth Trimebutine rates. Six hours after injection of tumor cells, MMP9 null mice showed a four-fold increase in the percent of tumor cells undergoing apoptosis compared to control mice. We conclude that MMP9 from your bone marrow contributes to the early survival and establishment of tumors in the lung and has no effect on subsequent growth. These results provide insights into the failure of MMP inhibitors in medical trials in individuals with late stage lung malignancy. Apoptosis Detection Kit (Chemicon International, Temecula, CA) relating to manufacturers directions. Nuclei were counterstained with Hoechst 33258. Labeling of tumor cells CellTracker? probe (CellTracker Reddish CMPTX) (Molecular Probes, Eugene, OR) (10M) was added to the cell tradition medium at a dilution of 1 1:1000. Cells were labeled for 30 min. Labeled cells were visualized using Axioplan 2 imaging microscope (Zeiss) and Openlab 4.0.2 software. Statistical Analysis All data generated using the experimental metastasis assays were analyzed using a non-parametrical (Mann-Whitney) method. Data generated using the orthotopic model were analyzed Trimebutine using Fishers precise test. (Statview software, SAS Institute). RESULTS Host MMPs contribute to the establishment of tumors in the lung In order to determine if host-derived MMPs contribute to lung tumor colonization, experimental metastasis assays were performed by injecting 3 x 105 Lewis lung carcinoma cells (LLC) into the tail vein of syngeneic C57Bl/6 wildtype mice or MMP2, MMP7 or MMP9 null mice. Two weeks after tail vein injection, the surface lung Trimebutine tumors were counted and measured. In contrast to earlier reports (15), we saw no difference in tumor quantity comparing control and MMP2 null mice (Fig. 1A). Remarkably, MMP7 null mice showed a 42% increase in tumor quantity compared to control mice (p=0.01), suggesting a protective effect of MMP7 on lung colonization (Fig. 1C). Most interestingly, MMP9 null mice showed an 81% reduction in tumor quantity compared to wildtype mice (p=0.0002) (Fig. 1E). The results from the MMP9 null mice are in agreement with those previously reported (16) although the effect of MMP9 ablation on tumor quantity was greater in our study. There was no significant difference in tumor size in any of the MMP null mice compared to wildtype mice (Fig. 1B,D,F), suggesting that these MMPs are not having an effect on the growth of tumors that successfully set up in the lung. These experiments display that different host-derived MMPs can have different effects on metastasis to the lung. Because MMP9 null mice showed probably the most dramatic phenotype, we chose to pursue this observation to understand the mechanism by which MMP9 contributes to lung tumor development. Open in a separate window Number 1 Host MMP contributions to lung tumor formation. (A) Quantity of surface lung tumors in control (n=12) and MMP2 null (n=12) mice 2 weeks after injection of 3 x 105 LLC cells i.v. (p=NS). (B) Tumor size in control and MMP2 null mice (p=NS). (C) Quantity of surface lung tumors in control (n=14) and MMP7 null (n=14) mice 2 weeks after injection of 3 x 105 LLC cells i.v. (*p=0.01). (D) Tumor size in control and MMP7 null mice (p=NS). (E) Quantity of surface lung tumors in control (n=13) and MMP9 null (n=11) mice 2 weeks after injection of 3 x 105 LLC cells i.v. (*p=0.0002). (F) Tumor size in control and MMP9 null mice (p=NS). MMP9 contributes to the establishment of a main tumor in the lung To test if sponsor MMP9 also has an Trimebutine effect within the establishment of main tumors in the lung, an orthotopic model of lung malignancy was founded by injecting human being lung carcinoma A549 cells directly into the lung via the trachea. This procedure produces distinct main tumors in the lung in 5 weeks (Fig. 2A). 1×106.